Terrier, Benjamin <br/><br/>
Late-onset neutropenia following rituximab results from a hematopoietic lineage competition due to an excessive BAFF-induced B-cell recovery.  [electronic resource] 

 -  Haematologica  Feb 2007 
 - e20-3 p.  digital 
<br/><br/> Publication Type: Case Reports; Journal Article 
<br/><br/><label>ISSN: </label>1592-8721 
<br/><br/><label>Standard No.: </label>10.3324/haematol.11031  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antibodies, Monoclonal--administration & dosage<br/>Antibodies, Monoclonal, Murine-Derived<br/>B-Cell Activating Factor--blood<br/>B-Lymphocytes--drug effects<br/>Bone Marrow--pathology<br/>Cell Lineage<br/>Cells, Cultured--drug effects<br/>Cyclophosphamide--administration & dosage<br/>Cytokines--blood<br/>Drug Therapy, Combination<br/>Female<br/>Humans<br/>Immunologic Factors--administration & dosage<br/>Lymphopoiesis--physiology<br/>Middle Aged<br/>Myelopoiesis--physiology<br/>Neutropenia--chemically induced<br/>Rituximab<br/>Time Factors<br/>Vidarabine--administration & dosage<br/>Waldenstrom Macroglobulinemia--blood